Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis

Laboratory Investigation

Volumn 84, Issue 1, 2004, Pages 21-28

  Mead, Richard James ^a   Neal, James William ^a   Griffiths, Mark Raymond ^a   Linington, Christopher ^b   Botto, Marina ^c   Lassmann, Hans ^d   Morgan, Bryan Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD59; Complement; Demyelination; Encephalomyelitis; Knockout

Indexed keywords

CD59 ANTIGEN; COMPLEMENT MEMBRANE ATTACK COMPLEX; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; INFLAMMATION; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; MYELIN SHEATH; NERVE FIBER; PATHOLOGY; SINGLE BLIND PROCEDURE;

ANIMALS; ANTIGENS, CD59; AXONS; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN SHEATH; SINGLE-BLIND METHOD;

EID: 85047693713     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700015     Document Type: Article

References (47)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952.
2. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody and complement-mediated demyelination. Ann Neurol 1998;43:465-471.
3. Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000;157:267-276.
4. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
5. Waxman SG. Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 1998;338:323-325.
6. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-1592.
7. Bornstein MB, Appel H. Tissue culture studies of demyelination. Ann NY Acad Sci 1965;122:280-286.
8. Liu WT, Vanguri P, Shin ML. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. J Immunol 1983;131:778-782.
9. Scolding NJ, Morgan BP, Houston WA, et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 1989;339:620-622.
10. Linington C, Lassmann H, Morgan BP, et al. Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol 1989;79:78-85.
11. Compston DA, Morgan BP, Campbell AK, et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316.
12. Linington C, Morgan BP, Scolding NJ, et al. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989;112:895-911.
13. Piddlesden SJ, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-564.
14. Piddlesden SJ, Storch MK, Hibbs M, et al. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994;152:5477-5484.
15. Nataf S, Carroll SL, Wetsel RA, et al. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J Immunol 2000;165:5867-5873.
16. Calida DM, Constantinescu C, Purev E, et al. Cutting edge: C3, a key component of complement activation, is not required for the development of myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis in mice. J Immunol 2001;166:723-726.
17. Vanguri P, Shin ML. Hydrolysis of myelin basic protein in human myelin by terminal complement complexes. J Biol Chem 1988;263:7228-7234.
18. Mead RJ, Singhrao SK, Neal JW, et al. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002;168:458-465.
19. Tran GT, Hodgkinson SJ, Carter N, et al. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J Immunol 2002;168:4293-4300.
20. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
21. Yam P, Petz LD, Tourtellotte WW, et al. Measurement of complement components in cerebral spinal fluid by radioimmunoassay in patients with multiple sclerosis. Clin Immunol Immunopathol 1980;17:492-505.
22. Mollnes TE, Vandvik B, Lea T, et al. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci 1987;78:17-28.
23. Scolding N, Linington C, Compston A. Immune mechanisms in the pathogenesis of demyelinating diseases. Autoimmunity 1989;4:131-142.
24. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
25. Morgan BP, Harris CL. Complement Regulatory Proteins. Academic Press: London, 1999.
26. Powell MB, Marchbank KJ, Rushmere NK, et al. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 1997;158:1692-1702.
27. Qian YM, Qin X, Miwa T, et al. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 2000;165:2528-2534.
28. Harris CL, Hanna SM, Mizuno M, et al. Characterization of the mouse analogues of CD59 using novel monoclonal antibodies: tissue distribution and functional comparison. Immunology 2003;109:117-126.
29. Holt DS, Botto M, Bygrave AE, et al. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 2001;98:442-449.
30. Espejo C, Penkowa M, Saez-Torres I, et al. Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice. Exp Neurol 2001;172:460-468.
31. Adelmann M, Wood J, Benzel I, et al. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 1995;63:17-27.
32. Stefferl A, Brehm U, Linington C. The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 2000, 123-133.
33. Coffey JC, McDermott KW. The regional distribution of myelin oligodendrocyte glycoprotein (MOG) in the developing rat CNS: an in vivo immunohistochemical study. J Neurocytol 1997;26:149-161.
34. Parker CJ. Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 1996;14:396-411.
35. Piddlesden SJ, Morgan BP. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J Neuroimmuol 1993;48:169-175.
36. Vedeler C, Ulvestad E, Bjorge L, et al. The expression of CD59 in normal human nervous tissue. Immunology 1994;82:542-547.
37. Zajicek J, Wing M, Skepper J, et al. Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. Lab Invest 1995;73:128-138.
38. Singhrao SK, Neal JW, Rushmere NK, et al. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 1999;79:1247-1259.
39. Singhrao SK, Neal JW, Rushmere NK, et al. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000;157:905-918.
40. Qin X, Miwa T, Aktas H, et al. Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b. Mamm Genome 2001;12:582-589.
41. Qin X, Krumrei N, Grubissich L, et al. Deficiency of the Mouse Complement Regulatory Protein mCd59b Results in Spontaneous Hemolytic Anemia with Platelet Activation and Progressive Male Infertility. Immunity 2003;18:217-227.
42. Oliver AR, Lyon GM, Ruddle NH. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 2003;171:462-468.
43. Bourquin C, Schubart A, Tobollik S, et al. Selective unresponsiveness to conformational B cell epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice. J Immunol 2003;171:455-461.
44. Parker CJ. Paroxysmal nocturnal hemoglobinuria and complement-mediated erythrocyte damage. Curr Opin Hematol 1994;1:151-156.
45. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990;323:1184-1189.
46. Yang LB, Li R, Meri S, et al. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci 2000;20:7505-7509.
47. Pinter C, Beltrami S, Caputo D, et al. Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis. J Neurovirol 2000;6:S42-S46.